Bhaskar Anand - Jun 14, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
SVP, Chief Accounting Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
Jun 14, 2023
Transactions value $
-$196,574
Form type
4
Date filed
6/16/2023, 04:03 PM
Previous filing
May 17, 2023
Next filing
Aug 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Options Exercise $42.7K +1.56K +6.08% $27.32 27.2K Jun 14, 2023 Direct
transaction RETA Class A common stock Sale -$239K -2.34K -8.6% $102.11 24.9K Jun 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right to buy) Options Exercise $0 -1.56K -6.25% $0.00 23.4K Jun 14, 2023 Class A common stock 1.56K $27.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $101.9841 to $102.52 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.